Overview

Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Status:
NOT_YET_RECRUITING
Trial end date:
2029-04-30
Target enrollment:
Participant gender:
Summary
This is A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase:
PHASE1
Details
Lead Sponsor:
Antengene Biologics Limited